Linked Life Data

16019525

Source:http://linkedlifedata.com/resource/pubmed/id/16019525

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2005-7-15
pubmed:abstractText
The decrease in treatment-related mortality by using reduced intensity conditioning and the well-proven immunological effect of the graft to multiple myeloma cells has increased the interest in using allogeneic stem cell transplantation in patients with multiple myeloma. The concept of a cytoreductive autograft followed by a dose-reduced allogeneic stem cell transplantation appears to be the most promising approach. Preliminary reports of several groups observed a treatment-related mortality at 1 year ranged from 0-17%. The rate of acute graft-vs.-host disease (GvHD) grade II-IV ranged from 32-44% and of chronic GvHD from 28-64%. The overall response rates for all studies ranged from 68-83%, including a high rate of complete remissions of 52-83%. The overall survival at 2 or 3 years was between 62% and 78%, and the progression-free survival between 54% and 56%. Despite the high rate of complete remissions after autologous-allogeneic tandem transplantation observed in nearly all trials, the relapse rate is quite considerable and exceeded nearly 40% at 2 years. Therefore, the reduced allogeneic treatment approach in patients with multiple myeloma has still to be improved and further preclinical and clinical research is focused on two major issues: (i) to further reduce treatment-related mortality and (ii) to enhance the remission status after transplantation, via adoptive immunotherapy inducing molecular remission and enhancing the cure rate of this approach.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1029-2403
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
46
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
813-21
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Autologous-allogeneic tandem stem cell transplantation in patients with multiple myeloma.
pubmed:affiliation
Bone Marrow Transplantation, University Hospital Hamburg-Eppendorf, Hamburg, Germany. nkroeger@uke.uni-hamburg.de
pubmed:publicationType
Journal Article, Review, Research Support, Non-U.S. Gov't